BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30887015)

  • 1. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
    Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
    Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
    Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens.
    Wu W; Huang Y; Guo J; Xie X; Li H; Cao Z; Wei H; Wu C
    Cancer Cytopathol; 2020 Aug; 128(8):545-552. PubMed ID: 32286726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
    Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
    Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.
    Roy-Chowdhuri S; Mehrotra M; Bolivar AM; Kanagal-Shamanna R; Barkoh BA; Hannigan B; Zalles S; Ye W; Duose D; Broaddus R; Staerkel G; Wistuba I; Medeiros LJ; Luthra R
    Mod Pathol; 2018 Jul; 31(7):1036-1045. PubMed ID: 29463880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy assay for pulmonary adenocarcinoma using supernatants from core-needle biopsy specimens.
    Kong F; Li Y; Guo R; Yang L; Di J; He L; Wang Z; Liu D; Li X
    Thorac Cancer; 2022 Jun; 13(12):1822-1826. PubMed ID: 35575062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
    Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
    Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of fine needle aspiration cytology and core biopsy histopathology with or without immunohistochemical staining in the subtyping of the non-small cell lung carcinomas: Experience from an academic centre in Turkey.
    Bayrak BY; Paksoy N; Vural Ç
    Cytopathology; 2021 May; 32(3):331-337. PubMed ID: 33145811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
    Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
    Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
    PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.
    Zheng G; Lin MT; Lokhandwala PM; Beierl K; Netto GJ; Gocke CD; Eshleman JR; McCarthy E; Illei PB
    Cancer Cytopathol; 2016 Oct; 124(10):744-753. PubMed ID: 27286239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic efficacy and molecular testing by combined fine-needle aspiration and core needle biopsy in patients with a lung nodule.
    Chen L; Jing H; Gong Y; Tam AL; Stewart J; Staerkel G; Guo M
    Cancer Cytopathol; 2020 Mar; 128(3):201-206. PubMed ID: 31913583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
    Isaka M; Serizawa M; Kenmotsu H; Koh Y; Takahashi S; Maniwa T; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Yamamoto N; Takahashi T; Ohde Y
    Clin Lung Cancer; 2017 Sep; 18(5):519-526.e1. PubMed ID: 28057436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.
    Zheng G; Tsai H; Tseng LH; Illei P; Gocke CD; Eshleman JR; Netto G; Lin MT
    Am J Clin Pathol; 2016 May; 145(5):696-702. PubMed ID: 27247373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.